Cleveland BioLabs to Report Third Quarter 2013 Financial Results and Provide Operational Update on November 6

Cleveland BioLabs to Report Third Quarter 2013 Financial Results and Provide
Operational Update on November 6

BUFFALO, N.Y., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) today announced that on November 6, 2013, it will report its
financial results for the third quarter and nine-month periods ended September
30, 2013, and will host a conference call at 10:00 a.m. ET.

Interested parties may participate by dialing 877-407-9205 (US) or
201-689-8054 (International), approximately five to ten minutes before the
call start time. A live webcast of the conference call will be available on
the investor page of the Cleveland BioLabs web site at www.cbiolabs.com.

A replay of the call will be available starting on November 6, 2013, at 1:00
p.m. ET through November 20, 2013, at 11:59 p.m. ET. Interested parties may
access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International)
and entering conference ID number 100723.An archived webcast of the
conference call will be available on the investor page of the Cleveland
BioLabs web site at www.cbiolabs.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep understanding of molecular and cellular mechanisms of biological stress
responses to develop a robust pipeline of compounds primarily focused on
oncology applications and mitigation of radiation injury. The company's lead
compound is being developed as both a radiation countermeasure and a cancer
treatment. The Company has three operating subsidiaries, Incuron, LLC, BioLabs
612, LLC and Panacela Labs, Inc., and strategic relationships with the
Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer
Institute Australia for Medical Research and the Armed Forces Radiobiology
Research Institute. To learn more about Cleveland BioLabs, Inc., please visit
the Company's website at http://www.cbiolabs.com.

Contact:
Rachel Levine, Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com

Cleveland BioLabs, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.